Novavax combined influenza/COVID-19 vaccine shows promise in animal study

2 minute read

A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo

Register now for FREE unlimited access to Reuters.com

May 10 (Reuters) - Novavax Inc (NVAX.O) said on Monday its combined flu and COVID-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.

The company said the NanoFlu/NVX-CoV2373 vaccine elicited robust responses to both influenza A and B and protected against the SARS-CoV-2 virus. (https://refini.tv/3bg25TM)

"Seasonal influenza and COVID-19 combination vaccines will likely be critical to combating emerging COVID-19 variants," said Russell Wilson, the executive vice president and NanoFlu general manager of Novavax.

Hamsters that received the combined vaccine had heightened levels of COVID-19 antibodies two weeks after the first immunization, which increased significantly after a second dose, compared to animals that received the COVID-19 vaccine, NVX-CoV2373, alone, the company said.

Novavax said it expects to start clinical studies of the combined vaccine by the end of 2021.

Register now for FREE unlimited access to Reuters.com
Reporting by Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel

Our Standards: The Thomson Reuters Trust Principles.